Antibody drug conjugate is a significant class of
highly potent bio drugs envisioned as a broad therapy for treatment
of cancer. Unlike chemotherapy, antibody drug conjugate are proposed
to mark and kill only cancer cells. Antibody drug conjugates are
compound molecules that comprise antibodies linked to a biologically
active cytotoxic drug.
By uniting the exclusive targeting capacities of
mAB with anti-cancer drugs, ADCs allow for subtle judgment between
healthy and diseased tissue. This entails that the antibody drug
conjugates kill only cancer cells and ensure that other dynamic cells
are less severely affected. This exceptional phenomenon of killing
only cancer cells increase the importance of use of ADCs, which would
indirectly boost growth of the global antibody drug conjugates
market.
Get an exclusive sample of this report :
https://www.coherentmarketinsights.com/insight/request-sample/181
Commercialization of 7-10 ADCs in the
following decade, would lead to revenue to surge to over US$ 10
billion over the forecast period of market
In terms of marketing, three antibody drug
conjugates have received regulatory approval. The U.S. FDA approved
one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to
treat acute myelogenous leukemia. The drug was subsequently withdrawn
in June 2010, leaving only two antibody drug conjugates in the
market. The two drugs marketed for ADCs are Brentuximab vedotin and
Trastuzumab emtansine, developed and manufactured by Seattle Genetics
and Millennium/Takeda and Genentech and Roche, respectively. Around
45 antibody drug conjugates molecules are under clinical trials, with
the preclinical pipeline expanding at a high rate. Of all the 45
molecules, around 25% are under Phase II or Phase III of development.
Frequently used cytotoxins for antibody drug conjugates under trials
include auristatin, calicheamicin, maytansine and duocarmycin.
Auristatin is the dominant compound accounting for over 50% of
antibody drug conjugates in clinical development. Roche has 10
compounds under clinical trials, and this is the most developed
pipeline of antibody drug conjugates. Globally, 70%-80% of antibody
drug conjugates manufacturing is currently outsourced. There are
limited number of contract manufacturers that have high-end
manufacturing equipment for development of cytotoxins.
Antibody drug conjugates market is still
in its infancy, with two approved ADCs to propel the market to two
digit billion dollar mark by 2020
The global antibody drug conjugates market is
segmented on the basis of drug and geography. On the basis of drug,
the market is divided into Adcetris and Kadcyla.
Major pharmaceutical company opt for
contract manufacturer for development and manufacture of antibody
drug conjugates
Regional segmentation of the antibody drug
conjugates market by Coherent Market Insights comprises North
America, Europe, Asia Pacific, Latin America, Middle East, and
Africa. Europe accounts for the largest share in the global market
mainly due to presence of many contract manufacturing companies with
advanced manufacturing equipment. Lonza is one of the top contract
manufacturing companies in Europe, which has operations across France
and Germany, with its headquarters in Switzerland. One of the
facilities operated by the company is a deck to chemical
manufacturing capabilities and develop peptides, small molecule
active pharmaceutical ingredients, highly potent active
pharmaceutical ingredients, cytotoxics agents, antibody drug
conjugates, and microbial products. The company also offer
proficiency in chemical, pharmaceutical, agrochemical and food
industries by providing clients with yields such as high-class active
substances, organic chemicals and intermediates.
Request to view table of content @
https://www.coherentmarketinsights.com/ongoing-insight/toc/181
Large number of clinical trial molecules
in pipeline to boost growth of antibody drug conjugates market
Key players operating the antibody drug conjugates
market include Hoffmann-La Roche Ltd, Seattle Genetics, Takeda,
ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex
Therapeutics, Synthon, and Progenics Pharmaceuticals. Major companies
in the antibody drug conjugates industry are constantly working on
research and development, as the market is largely untapped and offer
highly lucrative growth opportunities. For instance, there are only
two antibody drug conjugates available worldwide that are used to
treat cancer, and there are over 40 molecules under clinical trials.
Considering the alarmingly high incidence rate of cancer across the
globe, the antibody conjugates market is expected to ride on a wave
of positive growth in the foreseeable future.
About Coherent Market Insights:
Coherent Market Insights is a
prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations
related to emerging market trends, technologies, and potential
absolute dollar opportunity
No comments:
Post a Comment